

## GLP-1 Pipeline Update: February 2025

As the GLP-1 pipeline continues to grow, Prime actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The table below displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer published announcements or communications or are estimated based on study completion dates and may change as more information becomes available.

Drug/Dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	MASH	Alzheimer's disease
exenatide (Byetta/Bydureon Bcise)/SC	FDA-approved (Byetta only ages ≥ 10 years)											
dulaglutide (Trulicity)/SC	FDA-approved (ages ≥ 10 years)		FDA-approved									
liraglutide (Victoza)/SC	FDA-approved (ages ≥ 10 years)		FDA-approved									
liraglutide (Saxenda)/SC		FDA-approved (ages ≥ 12 years)										
liraglutide/insulin degludec (Xultophy)/SC	FDA-approved											
lixisenatide/insulin glargine (Soliqua)/SC	FDA-approved											
semaglutide (Ozempic)/SC	FDA-approved		FDA-approved		2026	FDA-approved	2027					
semaglutide 1.5–14 mg (Rybelsus)/oral	FDA-approved		early 2026									2027
semaglutide 25 mg, 50 mg (NN9932)/oral	2026	1H2026										
semaglutide (Wegovy)/SC		FDA-approved (ages ≥ 12 years)		FDA-approved					2026	FDA decision 2H2025		
tirzepatide (Mounjaro)/SC	FDA-approved											
tirzepatide (Zepbound)/SC		FDA-approved						FDA-approved		FDA decision 3Q2025		
cagrilintide + semaglutide/SC	2026	2027										

Drug/dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	MASH	Alzheimer's disease
orforglipron/oral	2027	2026						2027				
retatrutide/SC	2027	2027		2027					2027			
semaglutide (NN9931)/SC											1H2026	
semaglutide + insulin icodec/SC	2026											
survodutide/SC		2027		2027							2027	

## Glossary

CKD = Chronic kidney disease

CVD = Cardiovascular disease

FDA = Food and Drug Administration

GLP-1 = Glucagon-like peptide-1 receptor agonist

HF = Heart failure

MASH = Metabolic dysfunction-associated steatohepatitis

OA = Osteoarthritis

OSA = Obstructive sleep apnea

PAD = Peripheral arterial disease

SC = Subcutaneous

T2DM = Type 2 diabetes mellitus

## Disclaimer

*The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.*

*All brand names are property of their respective owners.*